EXEL - Exelixis, Inc.
NASDAQ
->
Healthcare
->
Biotechnology
Alameda,
United States
Type: Equity
EXEL price evolution
EXEL
| (in millions $) | 30 Oct 2024 | 28 Jul 2024 | 31 Mar 2024 | 31 Dec 2023 |
|---|---|---|---|---|
| Current assets | ||||
| Cash | $198.46 | $259.56 | $262.99 | |
| Short term investments | $803.54 | $703.7 | $732.31 | |
| Net receivables | $269.71 | $396.58 | $240.58 | $237.41 |
| Inventory | $21.01 | $20.61 | $21.11 | $17.32 |
| Total current assets | $1549.72 | $1477.44 | $1292.43 | $1317.96 |
| Long term investments | $432.31 | $629.56 | $728.72 | |
| Property, plant & equipment | $124.41 | $130.21 | $456.5 | $470.85 |
| Goodwill & intangible assets | $63.68 | $63.68 | $63.68 | |
| Total noncurrent assets | $1295.68 | $1511.32 | $1624.4 | |
| Total investments | $1235.85 | $1333.26 | $1461.03 | |
| Total assets | $2960.28 | $2773.12 | $2803.75 | $2942.36 |
| Current liabilities | ||||
| Accounts payable | $59.31 | $28.68 | $26.07 | $33.77 |
| Deferred revenue | ||||
| Short long term debt | ||||
| Total current liabilities | $394.35 | $345.7 | $373.01 | $394.28 |
| Long term debt | $198.02 | $201.47 | $189.94 | |
| Total noncurrent liabilities | $307.68 | $302.73 | $284.17 | |
| Total debt | $198.02 | $201.47 | $189.94 | |
| Total liabilities | $684.86 | $653.39 | $675.74 | $678.45 |
| Shareholders' equity | ||||
| Retained earnings | -$90.29 | -$199.97 | -$258.95 | -$173.35 |
| Other shareholder equity | $3.96 | -$5.15 | -$5.2 | -$3.75 |
| Total shareholder equity | $2119.73 | $2128.01 | $2263.91 | |
| (in millions $) | 31 Dec 2023 | 31 Jan 2023 | 31 Dec 2021 | 31 Dec 2020 |
|---|---|---|---|---|
| Current assets | ||||
| Cash | $262.99 | $501.19 | $647.17 | $319.22 |
| Short term investments | $732.31 | $807.27 | $819.9 | $887.32 |
| Net receivables | $237.41 | $214.78 | $282.65 | $160.88 |
| Inventory | $17.32 | $33.3 | $27.49 | $20.97 |
| Total current assets | $1317.96 | $1618.76 | $1834.75 | $1445.39 |
| Long term investments | $728.72 | $756.73 | $371.11 | $332.31 |
| Property, plant & equipment | $470.85 | $345.44 | $104.03 | $67.38 |
| Goodwill & intangible assets | $63.68 | $63.68 | $63.68 | $63.68 |
| Total noncurrent assets | $1624.4 | $1452.73 | $781.49 | $691.94 |
| Total investments | $1461.03 | $1564 | $1191.02 | $1219.63 |
| Total assets | $2942.36 | $3071.49 | $2616.24 | $2137.33 |
| Current liabilities | ||||
| Accounts payable | $33.77 | $32.67 | $24.26 | $23.63 |
| Deferred revenue | $6.58 | $8.74 | $3.75 | |
| Short long term debt | ||||
| Total current liabilities | $394.28 | $324.36 | $337.59 | $204.66 |
| Long term debt | $189.94 | $190.17 | $51.27 | $49.09 |
| Total noncurrent liabilities | $284.17 | $258.7 | $68.03 | $53.56 |
| Total debt | $189.94 | $190.17 | $51.27 | $49.09 |
| Total liabilities | $678.45 | $583.06 | $405.62 | $258.22 |
| Shareholders' equity | ||||
| Retained earnings | -$173.35 | -$34.23 | -$216.51 | -$447.57 |
| Other shareholder equity | -$3.75 | -$14.52 | -$0.76 | $4.48 |
| Total shareholder equity | $2263.91 | $2488.43 | $2210.61 | $1879.11 |
| (in millions $) | 30 Oct 2024 | 30 Jun 2024 | 31 Mar 2024 | 31 Dec 2023 |
|---|---|---|---|---|
| Revenue | ||||
| Total revenue | $539.54 | $637.18 | $425.23 | $479.65 |
| Cost of revenue | $17.67 | $21.26 | $21.75 | |
| Gross Profit | $522.21 | $619.51 | $403.97 | $457.9 |
| Operating activities | ||||
| Research & development | $211.15 | $227.69 | $244.67 | |
| Selling, general & administrative | $132.01 | $113.98 | $131.44 | |
| Total operating expenses | $334.37 | $343.64 | $374.51 | $376.11 |
| Operating income | $275.87 | $29.46 | $81.79 | |
| Income from continuing operations | ||||
| EBIT | $292.85 | $49.27 | $103.04 | |
| Income tax expense | $36.78 | $66.73 | $11.95 | $17.52 |
| Interest expense | $18.71 | |||
| Net income | ||||
| Net income | $117.97 | $226.12 | $37.32 | $85.52 |
| Income (for common shares) | $226.12 | $37.32 | $85.52 | |
| (in millions $) | 31 Dec 2023 | 31 Dec 2022 | 31 Dec 2021 | 31 Dec 2020 |
|---|---|---|---|---|
| Revenue | ||||
| Total revenue | $1830.21 | $1611.06 | $1434.97 | $987.54 |
| Cost of revenue | $72.55 | $57.91 | $52.87 | $36.27 |
| Gross Profit | $1757.66 | $1553.15 | $1382.1 | $951.27 |
| Operating activities | ||||
| Research & development | $1044.07 | $891.81 | $693.72 | $547.85 |
| Selling, general & administrative | $542.71 | $459.86 | $401.71 | $293.36 |
| Total operating expenses | $1586.78 | $1351.67 | $1095.43 | $841.21 |
| Operating income | $170.88 | $201.48 | $286.67 | $110.06 |
| Income from continuing operations | ||||
| EBIT | $257.52 | $234.35 | $294.15 | $130.84 |
| Income tax expense | $49.76 | $52.07 | $63.09 | $19.06 |
| Interest expense | ||||
| Net income | ||||
| Net income | $207.76 | $182.28 | $231.06 | $111.78 |
| Income (for common shares) | $207.76 | $182.28 | $231.06 | $111.78 |
| (in millions $) | 30 Oct 2024 | 30 Jun 2024 | 31 Mar 2024 | 31 Dec 2023 |
|---|---|---|---|---|
| Net income | $226.12 | $37.32 | $85.52 | |
| Operating activities | ||||
| Depreciation | $14.51 | $13.14 | $14.03 | |
| Business acquisitions & disposals | ||||
| Stock-based compensation | $25.35 | $19.11 | $24.31 | |
| Total cash flows from operations | $119.55 | $68.82 | $10.57 | |
| Investing activities | ||||
| Capital expenditures | -$6.57 | -$9.69 | -$13.13 | |
| Investments | $106.59 | $129.98 | $74.87 | |
| Total cash flows from investing | -$23.58 | $81.77 | $111.79 | $61.74 |
| Financing activities | ||||
| Dividends paid | ||||
| Sale and purchase of stock | -$249.4 | -$177.06 | -$200.19 | |
| Net borrowings | ||||
| Total cash flows from financing | -$440.77 | -$262.42 | -$184.05 | -$206.17 |
| Effect of exchange rate | ||||
| Change in cash and equivalents | -$4.65 | -$61.1 | -$3.43 | -$133.87 |
| (in millions $) | 31 Dec 2023 | 31 Dec 2022 | 31 Dec 2021 | 31 Dec 2020 |
|---|---|---|---|---|
| Net income | $207.76 | $182.28 | $231.06 | $111.78 |
| Operating activities | ||||
| Depreciation | $54.69 | $39.19 | $18.96 | $13.97 |
| Business acquisitions & disposals | ||||
| Stock-based compensation | $106.34 | $107.57 | $119.82 | $105.07 |
| Total cash flows from operations | $333.32 | $362.61 | $400.8 | $208.98 |
| Investing activities | ||||
| Capital expenditures | -$40.47 | -$27.71 | -$64.22 | -$30.34 |
| Investments | $136.01 | -$385.96 | $21.34 | -$100.87 |
| Total cash flows from investing | -$26.95 | -$524.41 | -$42.88 | -$131.22 |
| Financing activities | ||||
| Dividends paid | ||||
| Sale and purchase of stock | -$516.93 | $23.89 | $24.31 | $24.89 |
| Net borrowings | ||||
| Total cash flows from financing | -$546.05 | $0.59 | -$14.8 | -$25.13 |
| Effect of exchange rate | ||||
| Change in cash and equivalents | -$239.68 | -$161.21 | $343.12 | $52.63 |
News
Fundamentals
| Market cap | $10.48B |
|---|---|
| Enterprise value | N/A |
| Shares outstanding | 285.78M |
| Revenue | $2.08B |
|---|---|
| EBITDA | N/A |
| EBIT | N/A |
| Net Income | $466.92M |
| Revenue Q/Q | 14.33% |
| Revenue Y/Y | N/A |
| P/E ratio | 22.45 |
|---|---|
| EV/Sales | N/A |
| EV/EBITDA | N/A |
| EV/EBIT | N/A |
| P/S ratio | 5.04 |
| P/B ratio | N/A |
| Book/Share | N/A |
| Cash/Share | N/A |
| EPS | $1.63 |
|---|---|
| ROA | 16.27% |
| ROE | N/A |
| Debt/Equity | 0.30 |
|---|---|
| Net debt/EBITDA | N/A |
| Current ratio | 3.93 |
| Quick ratio | 3.88 |